Although this study provides real-world evidence of the impact of KRAS mutational status on first-line therapy in a large and well-controlled group of Stage IV NSCLC patients, it is obviously limited by its retrospective nature. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.